Laronidase is a fusion protein commercialized by JCR Pharmaceuticals, with a leading Phase II program in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Laronidase’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Laronidase is expected to reach an annual total of $38 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Laronidase Overview
JR-171 is under development for the treatment of Hurler syndrome. The drug candidate is a recombinant blood brain barrier penetrating acid alpha-L iduronidase. It is administered by intravenous route and developed based on J-brain cargo technology and J-MIG system. The drug candidate is an enzyme replacement therapy.
JCR Pharmaceuticals Overview
JCR Pharmaceuticals (JCR Pharma) is a biopharmaceutical company. It produces, purchases, and sells medical drugs, regenerative medicine products, and pharmaceutical raw materials. The company’s product portfolio includes Growject for growth hormone deficiency and short stature; Izcargo for Mucopolysaccharidosis type II; Agalsidase Beta BS IV Infusion for Fabry disease; Temcell HS Injection for acute graft-versus-host disease; and Epoetin and Darbepoetin Alfa BS injections for managing renal anemia. Its R&D pipeline focuses on advanced therapeutic solutions using its proprietary J-Brain Cargo and J-MIG System technologies. JCR Pharma is headquartered in Ashiya-Shi, Hyogo, Japan.
The company reported revenues of (Yen) JPY42,871 million for the fiscal year ended March 2024 (FY2024), an increase of 24.8% over FY2023. In FY2024, the company’s operating margin was 17.6%, compared to an operating margin of 14.4% in FY2023. In FY2024, the company recorded a net margin of 12.8%, compared to a net margin of 11% in FY2023.
The company reported revenues of JPY8,145 million for the first quarter ended June 2024, a decrease of 11% over the previous quarter.
For a complete picture of Laronidase’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
